Thus, to reveal how different therapy regimens and metabolic alterations may alter tumor metabolism and pinpoint potential mechanisms underpinning the anti-cancer effect(s) of the triple combination of KD, CP, and MET, we performed RNA-seq analysis on the more therapeutically-responsive SKNBE(2) xenografts. The gene discussed is MET; the disease is cancer.